Skip to content
Clinical Trials – home

Beclometasone Dipropionate Anhydrous: A Comprehensive Guide for Patients

4 / 8
trials open to patients / all trials
15+
Countries

In short

This article discusses clinical trials investigating the use of Beclometasone Dipropionate Anhydrous, a corticosteroid medication, in combination with other drugs for treating respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). The trials aim to evaluate the efficacy, safety, and tolerability of different inhaler formulations containing this drug compared to existing treatments.

At a glance

Conditions Studied
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Main Medications
Beclometasone Dipropionate Anhydrous, Formoterol Fumarate Dihydrate, Glycopyrronium Bromide
Administration Method
Pressurized Metered-Dose Inhalers (pMDI), Dry Powder Inhalers
Primary Objectives
Evaluate efficacy, safety, and tolerability of drug combinations
Key Endpoints
Lung function improvement (FEV1), reduction in exacerbations, quality of life measures
Study Designs
Randomized, double-blind, parallel-group, active-controlled
Trial Durations
Up to 52 weeks with follow-up periods
Patient Populations
Adults with moderate to severe asthma or COPD

What is Beclometasone Dipropionate Anhydrous?

Beclometasone Dipropionate Anhydrous is a potent corticosteroid medication used in the treatment of respiratory conditions. It is an anti-inflammatory drug that helps reduce swelling and irritation in the airways. This medication is commonly used in inhalers and is part of a class of drugs known as inhaled corticosteroids (ICS).

Medical Conditions Treated

Beclometasone Dipropionate Anhydrous is primarily used to treat:

  • Asthma: It is used for the long-term management of asthma, particularly in patients with moderate to severe asthma.
  • Chronic Obstructive Pulmonary Disease (COPD): It is also used in the treatment of COPD, a group of lung diseases that includes chronic bronchitis and emphysema.

How It Works

Beclometasone Dipropionate Anhydrous works by reducing inflammation in the airways. When inhaled, it: Decreases the production of inflammatory substances in the lungs Reduces swelling and irritation in the bronchial tubes Helps to prevent asthma attacks and COPD exacerbations This action helps to improve breathing and reduce symptoms such as wheezing, coughing, and shortness of breath.

Administration and Dosage

Beclometasone Dipropionate Anhydrous is typically administered via inhalation. It is available in various forms, including: Pressurized Metered Dose Inhaler (pMDI): A device that delivers a specific amount of medication in a fine mist form. Dry Powder Inhaler: A device that delivers the medication in a dry powder form. The dosage varies depending on the severity of the condition and the specific product being used. It's crucial to follow your healthcare provider's instructions carefully.

Combination Therapies

Beclometasone Dipropionate Anhydrous is often used in combination with other medications to provide more comprehensive treatment for respiratory conditions. Common combinations include: Beclometasone + Formoterol: This combination includes a long-acting beta-agonist (LABA) to provide both anti-inflammatory and bronchodilating effects. Beclometasone + Formoterol + Glycopyrronium: This triple combination therapy includes a long-acting muscarinic antagonist (LAMA) in addition to the ICS and LABA, providing enhanced bronchodilation for COPD patients. These combination therapies can provide more effective symptom control for some patients.

Clinical Studies and Efficacy

Several clinical studies have been conducted to evaluate the efficacy of Beclometasone Dipropionate Anhydrous and its combinations: A study comparing a triple combination of Beclometasone, Formoterol, and Glycopyrronium to a dual combination of Beclometasone and Formoterol in COPD patients showed improved lung function and reduced exacerbation rates with the triple therapy. Another study in asthma patients demonstrated that a combination of Beclometasone and Mepolizumab (an anti-IL-5 treatment) improved asthma control and reduced exacerbations. These studies highlight the effectiveness of Beclometasone Dipropionate Anhydrous in managing respiratory conditions, particularly when used in combination with other medications.

Potential Side Effects

While Beclometasone Dipropionate Anhydrous is generally well-tolerated, it may cause some side effects. Common side effects include: Throat irritation Hoarseness Oral thrush (fungal infection in the mouth) Cough Less common but more serious side effects may include: Increased risk of pneumonia (particularly in COPD patients) Adrenal suppression (with long-term use of high doses) Decreased bone density (with long-term use) It's important to discuss any side effects with your healthcare provider.

Precautions and Contraindications

Certain precautions should be taken when using Beclometasone Dipropionate Anhydrous: Inform your doctor if you have any fungal, bacterial, or viral infections before starting treatment. If you're pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider. Long-term use should be monitored by a healthcare professional to minimize potential systemic effects. This medication is not suitable for treating acute asthma attacks or COPD exacerbations - a fast-acting "rescue" inhaler should be used for these situations. Always follow your doctor's instructions and do not adjust your dosage without consulting your healthcare provider.

Questions people often ask

Conditions where Beclometasone Dipropionate Anhydrous is being studied

Each condition opens its own overview and trial list

Trials with Beclometasone Dipropionate Anhydrous

Recruiting trials first

See all 8 →
Quick filters
  • Participants:Adults
  • Participants:Adults
  • Participants:All ages
  • Participants:Children
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.